Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Sunday, September 11, 2016

Update: MEBO Metabolomic Profiling Research Study

Update on the
MEBO Metabolomic Profiling Study

On August 18, 2016, The status of the MEBO Metabolomic Profiling Research Study, NCT02683876 was changed from 'Recruiting' to 'Active, not recruiting.' This means that we are not taking any more volunteers for this study at this time. However, if you wish to be put on a wait list in case the results merit that the study continue forward, please express your interest in doing so via email at, Please do not call on the phone, as it is not always manned with a volunteer. MEBO has a wholly volunteer staff and no one has volunteered to answer the phones at this time. Your email will be answered in the order in which it was received. Thank you for your consideration to this matter.

As of today, Sept 11th, the University of Alberta lab has received 10 samples in good condition, 2 kits were returned as undeliverable to address given, and the lab is still waiting for the 15 outstanding samples. Everything is at a standstill due to the 15 outstanding samples. If you are an active participant in this study and have already received your kit, please return your samples as soon as possible because analysis of all the samples will be carried out once all have been received by the lab. The sooner you send in your samples, the faster we can move forward with the study. If you have changed your mind and do not plan to ship your sample, please let us know so that we can take this into account. Thank you.

Since this is an exploratory study, there is no guarantee that significant results will arise from it, but as MEBO has stated in the MEBO Mission, we are committed to pursue research not only into TMAU, but also to try to discover other causes of uncontrollable body and/or breath odor conditions.

MEBO Research’s Mission is to initiate formal scientific research into rare genetic metabolic diseases, particularly those resulting in systemic, difficult to control body malodor and halitosis conditions, including but not limited to Trimethylaminuria. In addition, studies will be initiated to analyze and categorize gut microbiota and to characterize the genes that the microbes are expressing in an effort to identify and understand microbial communities that could produce malodor symptoms, and to identify effective targeted course of treatment to control symptoms, and preferably cure the condition of our international body odor community.

I thank all the volunteer participants in this program for their contribution to this cause.


María de la Torre
Founder and Executive Director

A Public Charity (em português)
MEBO's Blog (English)
El Blog de MEBO (español)

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

Please use your credit card to make your donation to MEBO.

Subscribe for latest posts : Enter your email address:

Delivered by FeedBurner


Post a Comment